Literature DB >> 15073377

Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2.

Xander H T Wehrens1, Stephan E Lehnart, Steven R Reiken, Shi-Xian Deng, John A Vest, Daniel Cervantes, James Coromilas, Donald W Landry, Andrew R Marks.   

Abstract

Ventricular arrhythmias can cause sudden cardiac death (SCD) in patients with normal hearts and in those with underlying disease such as heart failure. In animals with heart failure and in patients with inherited forms of exercise-induced SCD, depletion of the channel-stabilizing protein calstabin2 (FKBP12.6) from the ryanodine receptor-calcium release channel (RyR2) complex causes an intracellular Ca2+ leak that can trigger fatal cardiac arrhythmias. A derivative of 1,4-benzothiazepine (JTV519) increased the affinity of calstabin2 for RyR2, which stabilized the closed state of RyR2 and prevented the Ca2+ leak that triggers arrhythmias. Thus, enhancing the binding of calstabin2 to RyR2 may be a therapeutic strategy for common ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073377     DOI: 10.1126/science.1094301

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  159 in total

Review 1.  A systematic comparison of exercise training protocols on animal models of cardiovascular capacity.

Authors:  Rui Feng; Liyang Wang; Zhonguang Li; Rong Yang; Yu Liang; Yuting Sun; Qiuxia Yu; George Ghartey-Kwansah; Yanping Sun; Yajun Wu; Wei Zhang; Xin Zhou; Mengmeng Xu; Joseph Bryant; Guifang Yan; William Isaacs; Jianjie Ma; Xuehong Xu
Journal:  Life Sci       Date:  2018-12-03       Impact factor: 5.037

Review 2.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Cardiac ryanodine receptor phosphorylation: target sites and functional consequences.

Authors:  Donald M Bers
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

4.  Profile of Andrew R. Marks.

Authors:  Philip Downey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

5.  Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes.

Authors:  Y-J Chen; Y-C Chen; W Wongcharoen; C-I Lin; S-A Chen
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 6.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

7.  Integrins protect cardiomyocytes from ischemia/reperfusion injury.

Authors:  Hideshi Okada; N Chin Lai; Yoshitaka Kawaraguchi; Peter Liao; Jeffrey Copps; Yasuo Sugano; Sunaho Okada-Maeda; Indroneal Banerjee; Jan M Schilling; Alexandre R Gingras; Elizabeth K Asfaw; Jorge Suarez; Seok-Min Kang; Guy A Perkins; Carol G Au; Sharon Israeli-Rosenberg; Ana Maria Manso; Zheng Liu; Derek J Milner; Stephen J Kaufman; Hemal H Patel; David M Roth; H Kirk Hammond; Susan S Taylor; Wolfgang H Dillmann; Joshua I Goldhaber; Robert S Ross
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

8.  Sudden infant death syndrome in mice with an inherited mutation in RyR2.

Authors:  Nitin Mathur; Subeena Sood; Sufen Wang; Ralph J van Oort; Satyam Sarma; Na Li; Darlene G Skapura; J Henri Bayle; Miguel Valderrábano; Xander H T Wehrens
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12

9.  Effects of K-201 on the calcium pump and calcium release channel of rat skeletal muscle.

Authors:  Janos Almassy; Monika Sztretye; Balazs Lukacs; Beatrix Dienes; Laszlo Szabo; Peter Szentesi; Guy Vassort; Laszlo Csernoch; Istvan Jona
Journal:  Pflugers Arch       Date:  2008-05-06       Impact factor: 3.657

10.  Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy.

Authors:  Jérémy Fauconnier; Jérôme Thireau; Steven Reiken; Cécile Cassan; Sylvain Richard; Stefan Matecki; Andrew R Marks; Alain Lacampagne
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.